Resona Asset Management Co. Ltd. Sells 3,558 Shares of United Therapeutics Corporation $UTHR

Resona Asset Management Co. Ltd. reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 16.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,282 shares of the biotechnology company’s stock after selling 3,558 shares during the period. Resona Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $7,672,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after acquiring an additional 2,655 shares during the period. Park Avenue Securities LLC boosted its holdings in shares of United Therapeutics by 1.7% during the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after acquiring an additional 39 shares during the period. Public Employees Retirement System of Ohio grew its position in shares of United Therapeutics by 0.7% in the second quarter. Public Employees Retirement System of Ohio now owns 15,580 shares of the biotechnology company’s stock valued at $4,477,000 after purchasing an additional 103 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of United Therapeutics by 17.0% during the second quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock worth $5,612,000 after purchasing an additional 2,840 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $473.36 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The firm has a market cap of $20.38 billion, a P/E ratio of 17.94, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84. The business’s fifty day moving average is $487.69 and its 200-day moving average is $416.98.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.39 earnings per share. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 536,864 shares of company stock valued at $255,191,362. 10.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.